

30th March 2005



Eastland Medical
Systems LTD

The Manager,
Company Announcements Platform,
Australian Stock Exchange,
Level 4, 20 Bridge Street,
Sydney. N.S.W. 2000

By E-lodgement of 2 pages.

MEDIA RELEASE.
TGA Approval for Retractable Syringe Manufacturer

Eastland Medical Systems (Eastland) has achieved a major milestone in its programme to introduce cost effective safer alternatives to the industry standard hypodermic needles and syringes currently in use in hospitals and clinics throughout Australia.

A key aspect of Eastlands business model has been to develop and market a comprehensive range of safer injectable devices to ensure the wide range of market needs is met. As part of this strategy Eastland has now reached the final stage in its plan to introduce to market a comprehensive range of easy to use, cost effective retractable syringes to both the Australian and International markets. This product range will be marketed under the RETRACTA name.

Eastland has now received confirmation from the TGA (Therapeutic Goods Administration) that registration has been granted for the contract manufacturer of the new range of manual retractable syringes Eastland intends to launch in Australia in the near future. The manufacturer is one of the largest medical device companies in China manufacturing to the highest international standards and with the capacity to meet both Australian and International demand.

The RETRACTA range of manual retractable syringes will be available in 1ml, 3ml, 5 ml and 10ml sizes which represent more than 95% of the devices used in the Australian market.

Unlike some automatic and manual retractable devices, the RETRACTA 3ml, 5ml and 10 ml devices all have interchangeable needle mounts enabling the healthcare worker to use any standard needle with the device, thereby ensuring the syringe has the same flexibility as the standard devices currently in use. A further significant benefit is the fact that there is no "dead space" enabling RETRACTA to be used for critical applications such as administration of insulin for diabetes and heparin for anticoagulant therapy. The price to market of RETRACTA is expected to be significantly less than that of automatic retractable devices now in development by other companies.

Application for registration of the RETRACTA syringes has now been lodged with the TGA and full approval is anticipated in approximately 10 weeks time. Upon approval Eastland will move quickly to introduce these products directly to market through its marketing and distribution arm Medical Industries Australia (MIA). The new expanded MIA National Distribution Centre in Sydney has the capacity to handle these products both for Australia and Internationally.

Unit 6
680 Murray Street
West Perth
Western Australia
6005
PO Box 898
West Perth
Western Australia
6872

T 61 8 9481 1844
F 61 8 9486 4998

ACN 060 987 250

European (CE) accreditation for the devices been achieved for the products, and the technical files are now with Eastlands associate companies Health In Form in South Africa and Eastland Medical Systems PLC in the UK. Preparation of the applications for regulatory approval for RETRACTA in these markets is now underway.

CEO Mr Don O'Sullivan said "This is a very exciting step forward in bringing the first of our range of cost effective safer injection devices to market not only in Australia but particularly in Africa and Europe where the potential markets are much larger. We believe the work done to date has created an organisation with the people and infrastructure required to deliver success in this marketplace."



Trevor Strahan.
Company Secretary
Eastland Medical Systems Limited

Don O'Sullivan – 08 9481-1844 David Whitelaw- 08 9481-1844